VARGADO data
Vargatef ® plus docetaxel could be an option after failure of immunotherapy in lung cancerResults from a real-world study1 support a recent update to the ESMO guidelines2 recommending nintedanib (Vargatef®) plus docetaxel following first-line chemotherapy (+/- immunotherapy) in advanced NSCLC of adenocarcinoma histology
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Adenocarcinoma | Cancer & Oncology | Chemotherapy | Docetaxel | Immunotherapy | Non-Small Cell Lung Cancer | Research | Taxotere